2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.096 Jeremy Kao NACLC23 Abstract

PP01.096 Jeremy Kao NACLC23 Abstract

Pdf Summary

The study aimed to characterize the distribution of DNA damage repair (DDR) gene mutations in lung cancer patients at an academic medical center that primarily serves an underserved, underinsured population. The researchers analyzed genetic data from 235 lung cancer patients seen at the University of Illinois Chicago between 2015 and 2023.<br /><br />They identified DDR gene mutations in 28.5% of the entire population. The frequency of DDR mutations varied among different subtypes of lung cancer, with the highest frequency observed in adenosquamous carcinoma (50%) and adenocarcinoma (33.5%). The most frequent DDR mutations in adenocarcinoma were ARID1A, CHEK2, BRCA2, ATM, and MUTYH. In neuroendocrine carcinoma, the most frequent DDR mutations were ARID1A, ATM, CHEK2, FANCC, and MLH3.<br /><br />The study also found a significant difference in tumor mutational burden (TMB) between the DDR mutation positive group and the DDR mutation negative group. The DDR positive group had a higher mean TMB compared to the DDR negative group.<br /><br />The results of this study highlight the varied distribution of DDR mutations in lung cancer patients from an underserved population. Future studies will focus on further investigating the associations between the presence of DDR mutations and clinical outcomes such as survival rates and response to treatment. Additionally, the researchers will explore the relationship between DDR mutations and socioeconomic factors.<br /><br />Overall, this study provides valuable insights into the prevalence and impact of DDR mutations in lung cancer patients, particularly in an underserved population, and lays the groundwork for future research and potential targeted therapies.

Keywords

DNA damage repair gene mutations

lung cancer patients

academic medical center

underserved population

genetic data analysis

DDR gene mutations

adenosquamous carcinoma

adenocarcinoma

neuroendocrine carcinoma

tumor mutational burden